Patents Assigned to Teikoku Pharma USA, Inc.
-
Patent number: 10987342Abstract: Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.Type: GrantFiled: October 3, 2014Date of Patent: April 27, 2021Assignee: Teikoku Pharma USA, Inc.Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
-
Patent number: 10918607Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: October 25, 2013Date of Patent: February 16, 2021Assignee: Teikoku Pharma USA, Inc.Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
-
Patent number: 10874642Abstract: Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.Type: GrantFiled: September 30, 2019Date of Patent: December 29, 2020Assignee: Teikoku Pharma USA, Inc.Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
-
Patent number: 10842770Abstract: Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.Type: GrantFiled: April 29, 2011Date of Patent: November 24, 2020Assignee: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta
-
Patent number: 10772871Abstract: Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.Type: GrantFiled: October 3, 2014Date of Patent: September 15, 2020Assignee: Teikoku Pharma USA, Inc.Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
-
Patent number: 10617655Abstract: Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.Type: GrantFiled: December 18, 2018Date of Patent: April 14, 2020Assignee: Teikoku Pharma USA, Inc.Inventors: Adchara Pongpeerapat, Bret Berner, Kensuke Murata
-
Patent number: 10357463Abstract: Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: March 9, 2018Date of Patent: July 23, 2019Assignee: Teikoku Pharma USA, Inc.Inventor: Kensuke Murata
-
Patent number: 10188616Abstract: Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.Type: GrantFiled: June 15, 2018Date of Patent: January 29, 2019Assignee: Teikoku Pharma USA, Inc.Inventors: Adchara Pongpeerapat, Bret Berner, Kensuke Murata
-
Patent number: 10022340Abstract: Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.Type: GrantFiled: August 29, 2014Date of Patent: July 17, 2018Assignee: Teikoku Pharma USA, Inc.Inventors: Adchara Pongpeerapat, Bret Berner, Kensuke Murata
-
Patent number: 9949935Abstract: Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: March 23, 2015Date of Patent: April 24, 2018Assignee: Teikoku Pharma USA, Inc.Inventor: Kensuke Murata
-
Patent number: 9913812Abstract: Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine oxidase inhibitors are also provided.Type: GrantFiled: November 2, 2012Date of Patent: March 13, 2018Assignee: Teikoku Pharma USA, Inc.Inventors: Susan Meier-Davis, Jianye Wen, Richard D. Hamlin
-
Patent number: 9827207Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: November 5, 2015Date of Patent: November 28, 2017Assignee: Teikoku Pharma USA, Inc.Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
-
Patent number: 9763880Abstract: Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.Type: GrantFiled: March 10, 2016Date of Patent: September 19, 2017Assignee: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta
-
Patent number: 9597301Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: March 16, 2015Date of Patent: March 21, 2017Assignee: Teikoku Pharma USA, Inc.Inventors: Jianye Wen, Richard D. Hamlin
-
Patent number: 9579296Abstract: The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.Type: GrantFiled: August 27, 2015Date of Patent: February 28, 2017Assignee: Teikoku Pharma USA, Inc.Inventors: Edward Kisak, Nadir Buyuktimkin, Servet Buyuktimkin, John Newsam, Jianye Wen, Jutaro Shudo, Amit Jain
-
Patent number: 9427435Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.Type: GrantFiled: September 22, 2014Date of Patent: August 30, 2016Assignees: Teikoku Pharma USA, Inc., Techno Guard Co., Ltd.Inventors: Kiichiro Nabeta, Toru Hibi
-
Patent number: 9421356Abstract: An integrated iontophoresis skin-worn patch and method for delivering a therapeutically effective amount of a corticosteroid drug compound in a systemically-safe and skin-safe manner for site-specific treatment of inflammation pain is disclosed.Type: GrantFiled: August 27, 2008Date of Patent: August 23, 2016Assignee: Teikoku Pharma USA, Inc.Inventors: Carter R. Anderson, Russell L. Morris, Robert Cohen, William V. Fowler
-
Publication number: 20160206560Abstract: Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.Type: ApplicationFiled: March 10, 2016Publication date: July 21, 2016Applicant: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta
-
Patent number: 9339856Abstract: Devices for use in the disposal of pharmaceutical compositions are provided. Aspects of the devices include: a support having a surface; an activated carbon layer present on the surface; and an adhesive for stably associating a pharmaceutical composition with the activated carbon layer upon application of the pharmaceutical composition to the activated carbon layer. Also provided are methods of using the devices and kits containing the devices.Type: GrantFiled: June 13, 2014Date of Patent: May 17, 2016Assignee: Teikoku Pharma USA, Inc.Inventors: William V. Fowler, Carter R. Anderson
-
Patent number: 9308195Abstract: Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.Type: GrantFiled: December 9, 2014Date of Patent: April 12, 2016Assignee: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta